<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352660</url>
  </required_header>
  <id_info>
    <org_study_id>151621</org_study_id>
    <nct_id>NCT04352660</nct_id>
  </id_info>
  <brief_title>Subconjunctival Versus Direct Mitomycin C in Trabeculectomy</brief_title>
  <official_title>Subconjunctival Versus Direct Scleral Application of Mitomycin-C in Trabeculectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trabeculectomy is routinely used as a surgical treatment for open angle glaucoma. Success of
      trabeculectomy is greatly augmented by the use of antimetabolites to inhibit wound healing,
      specifically Mitomycin C (MMC). MMC can be applied to the eye at various sites,
      concentrations and times. This study aims to compare the two application routes that are
      commonly employed: subconjunctival pre-operative injection and intraoperative direct scleral
      application in terms of IOP lowering effect, bleb appearance and complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trabeculectomy is widely used as a surgical treatment of uncontrolled open glaucoma. Success
      of trabeculectomy at halting or slowing glaucoma progression primarily relies on the extent
      of conjunctival and sclera wound healing. The success rates of trabeculectomy increased
      dramatically with the introduction of anti-metabolites. For more than two decades mitomycin-c
      (MMC), a chemotherapeutic agent capable of decreasing fibroblast activity and modulating
      wound healing at the bleb, has been used with trabeculectomy. The complications of MMC are
      well known and several studies have described various methods of application based on
      exposure time, dose and surface area. Numerous retrospective and prospective studies have
      compared the efficacy of MMC applied beneath the conjunctival flap with soaked sponges versus
      intrascleral application. In 2008, Lee et al. first described an alternative route of
      application: subconjunctival injection of MMC directly into the intra-Tenon area. Seventy-six
      eyes with primary and secondary open angle glaucoma underwent trabeculectomy with this
      approach and were followed for one year post-operatively. Eighty-six percent of eyes achieved
      an IOP &lt;21 mm Hg and 57% an IOP&lt;14 mm Hg at one year without adjunctive drops. Transient
      complications included hyphema, bleb leak and choroidal detachment. The advantages of
      injected MMC are primarily in controlling the exact dosage and area of application and
      reduced surgical time. Lim et al. retrospectively reviewed the outcomes of trabeculectomy in
      57 eyes using sponge application directly to the sclera versus intra-tenon injection. IOP was
      significantly lower in the injection group at 1 month, 1, 2, and 3 years. Trabeculectomy
      success (IOP&lt;21mm Hg or IOP &gt;20% below baseline without medications or additional surgery)
      was greater in the injection group at 3 years. The sponge group experienced more encapsulated
      blebs but complication rates were similar in both groups. To date, there have been no
      prospective studies comparing the IOP-lowering efficacy and safety of intra-tenon injection
      versus direct scleral application of MMC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Actual">April 14, 2019</completion_date>
  <primary_completion_date type="Actual">April 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Intraocular Pressure Reduction Thresholds</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients achieving at least a 30% mean intraocular pressure reductions from baseline and with an intraocular pressure &lt;21 mm Hg. Subjects that met this criteria without the use of intraocular pressure lowering medications were classified as &quot;Complete Success.&quot; Subjects that met this criteria but required the use of intraocular pressure lowering medications were classified as &quot;Qualified Success.&quot; Subjects that failed to meet this criteria were classified as &quot;Failure.&quot; Subjects that failed to meet this criteria and required additional glaucoma surgery were classified as &quot;Complete Failure.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleb Morphology</measure>
    <time_frame>6 months</time_frame>
    <description>Bleb morphology at 6 months was graded using Indiana Bleb Appearance Grading Scale. Bleb height was graded on a scale of 0 to 3 (0: flat bleb without visible elevation, 1: low bleb elevation, 2: moderate bleb elevation, 3: high bleb elevation). Bleb extent was graded on a scale of 0 to 3 (0: no visible bleb extent to less than 1 clock hour, 1: extent equal to or greater than 1 clock hour but less than 2 clock hours, 2: extent equal to or greater than 2 clock hours but less than 4 clock hours, 3: extent equal to or greater than 4 clock hours). Bleb vascularity was graded on a scale of 0 to 4 (0: avascular/white, 1: avascular/cystic, 2: mild vascularity, 3: moderate vascularity, 4: extensive vascularity). Scales are descriptive and do not necessarily represent better or worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medications</measure>
    <time_frame>6 months</time_frame>
    <description>Number of intraocular pressure lowering medications used by the patient at follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in visual acuity from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Complications</measure>
    <time_frame>6 months</time_frame>
    <description>Number of eyes that experienced surgical complications following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Additional Surgery</measure>
    <time_frame>6 months</time_frame>
    <description>Number of eyes requiring additional surgery from each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Interventions</measure>
    <time_frame>6 months</time_frame>
    <description>Mean number of postoperative interventions (needling, antifibrotic injections) performed in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Injection group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MMC delivered by preoperative subconjunctival injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sponge group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C injection</intervention_name>
    <description>MMC delivered by preoperative subconjunctival injection</description>
    <arm_group_label>Injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C sponge</intervention_name>
    <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
    <arm_group_label>Sponge group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  medically uncontrolled glaucoma

          -  healthy and freely mobile conjunctiva in superior bulbar region

        Exclusion Criteria:

          -  previous incisional glaucoma surgery

          -  no light perception vision

          -  pregnant or nursing women

          -  iris neovascularization or proliferative retinopathy

          -  iridocorneal endothelial syndrome

          -  chronic or recurrent uveitis

          -  steroid-induced glaucoma

          -  pathologic myopia or refractive error less than -6.00 diopters

          -  unwillingness or inability to give consent

          -  inability to return for scheduled protocol visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiun L Do, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert N Weinreb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Xu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <results_first_submitted>May 28, 2020</results_first_submitted>
  <results_first_submitted_qc>June 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2020</results_first_posted>
  <last_update_submitted>June 14, 2020</last_update_submitted>
  <last_update_submitted_qc>June 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jiun Do</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>trabeculectomy, mitomycin-C, glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04352660/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Injection Group</title>
          <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
        </group>
        <group group_id="P2">
          <title>Sponge Group</title>
          <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Injection Group</title>
          <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
        </group>
        <group group_id="B2">
          <title>Sponge Group</title>
          <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" spread="13.4"/>
                    <measurement group_id="B2" value="74.2" spread="9.5"/>
                    <measurement group_id="B3" value="72.0" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Primary open angle glaucoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pseudoexfoliation glaucoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pigmentary glaucoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic angle closure glaucoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Acuity</title>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.31" spread="0.34"/>
                    <measurement group_id="B2" value="0.36" spread="0.52"/>
                    <measurement group_id="B3" value="0.335" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Visual Field Mean Deviation</title>
          <description>Visual field mean deviation is measured in decibels (dB) and is the amount of visual field loss compared to age matched controls (people with no eye diseases or visual field loss). The brightness of flashes of light is measured in decibels and used to test the peripheral visual field. Subjects able to see dimmer lights than age matched controls will have positive values. Subjects who require brighter stimuli than age matched controls will have negative values.</description>
          <units>decibels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-17.19" spread="7.90"/>
                    <measurement group_id="B2" value="-15.87" spread="8.09"/>
                    <measurement group_id="B3" value="-16.53" spread="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Pattern Standard Deviation</title>
          <description>Visual field pattern standard deviation is measured in decibels (dB) and is the amount of irregular visual field loss compared to age matched controls (people with no eye diseases or visual field loss). The absolute values of the difference between visual field threshold value and the average visual field sensitivity are summed. Subjects with focal visual field defects will have a large pattern standard deviation. Subjects with normal or diffuse visual field defects will have a small pattern standard deviation.</description>
          <units>decibels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.4" spread="3.6"/>
                    <measurement group_id="B2" value="8.9" spread="3.2"/>
                    <measurement group_id="B3" value="9.15" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Intraocular Pressure</title>
          <description>Intraocular pressure is measured in millimeters of mercury . The intraocular pressure is measured in subjects using Goldmann applanation tonometry.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="7.2"/>
                    <measurement group_id="B2" value="21.8" spread="9.3"/>
                    <measurement group_id="B3" value="21.45" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IOP Goal</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" spread="0.9"/>
                    <measurement group_id="B2" value="12.7" spread="2.2"/>
                    <measurement group_id="B3" value="12.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Medications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Intraocular Pressure Reduction Thresholds</title>
        <description>Percentage of patients achieving at least a 30% mean intraocular pressure reductions from baseline and with an intraocular pressure &lt;21 mm Hg. Subjects that met this criteria without the use of intraocular pressure lowering medications were classified as &quot;Complete Success.&quot; Subjects that met this criteria but required the use of intraocular pressure lowering medications were classified as &quot;Qualified Success.&quot; Subjects that failed to meet this criteria were classified as &quot;Failure.&quot; Subjects that failed to meet this criteria and required additional glaucoma surgery were classified as &quot;Complete Failure.&quot;</description>
        <time_frame>6 months</time_frame>
        <population>14 subjects in the Injection group were lost to follow up at the 6 month postoperative visit. 10 subjects from the Sponge group were lost to follow up at the 6 month postoperative visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Injection Group</title>
            <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Sponge Group</title>
            <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Intraocular Pressure Reduction Thresholds</title>
          <description>Percentage of patients achieving at least a 30% mean intraocular pressure reductions from baseline and with an intraocular pressure &lt;21 mm Hg. Subjects that met this criteria without the use of intraocular pressure lowering medications were classified as &quot;Complete Success.&quot; Subjects that met this criteria but required the use of intraocular pressure lowering medications were classified as &quot;Qualified Success.&quot; Subjects that failed to meet this criteria were classified as &quot;Failure.&quot; Subjects that failed to meet this criteria and required additional glaucoma surgery were classified as &quot;Complete Failure.&quot;</description>
          <population>14 subjects in the Injection group were lost to follow up at the 6 month postoperative visit. 10 subjects from the Sponge group were lost to follow up at the 6 month postoperative visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Qualified Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleb Morphology</title>
        <description>Bleb morphology at 6 months was graded using Indiana Bleb Appearance Grading Scale. Bleb height was graded on a scale of 0 to 3 (0: flat bleb without visible elevation, 1: low bleb elevation, 2: moderate bleb elevation, 3: high bleb elevation). Bleb extent was graded on a scale of 0 to 3 (0: no visible bleb extent to less than 1 clock hour, 1: extent equal to or greater than 1 clock hour but less than 2 clock hours, 2: extent equal to or greater than 2 clock hours but less than 4 clock hours, 3: extent equal to or greater than 4 clock hours). Bleb vascularity was graded on a scale of 0 to 4 (0: avascular/white, 1: avascular/cystic, 2: mild vascularity, 3: moderate vascularity, 4: extensive vascularity). Scales are descriptive and do not necessarily represent better or worse outcomes.</description>
        <time_frame>6 months</time_frame>
        <population>In the injection group, 14 subjects were lost to follow up and 17 subjects did not undergo bleb assessments at 6 months.In the sponge group, 10 subjects were lost to follow up and 20 subjects did not undergo bleb assessments at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Injection Group</title>
            <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Sponge Group</title>
            <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
          </group>
        </group_list>
        <measure>
          <title>Bleb Morphology</title>
          <description>Bleb morphology at 6 months was graded using Indiana Bleb Appearance Grading Scale. Bleb height was graded on a scale of 0 to 3 (0: flat bleb without visible elevation, 1: low bleb elevation, 2: moderate bleb elevation, 3: high bleb elevation). Bleb extent was graded on a scale of 0 to 3 (0: no visible bleb extent to less than 1 clock hour, 1: extent equal to or greater than 1 clock hour but less than 2 clock hours, 2: extent equal to or greater than 2 clock hours but less than 4 clock hours, 3: extent equal to or greater than 4 clock hours). Bleb vascularity was graded on a scale of 0 to 4 (0: avascular/white, 1: avascular/cystic, 2: mild vascularity, 3: moderate vascularity, 4: extensive vascularity). Scales are descriptive and do not necessarily represent better or worse outcomes.</description>
          <population>In the injection group, 14 subjects were lost to follow up and 17 subjects did not undergo bleb assessments at 6 months.In the sponge group, 10 subjects were lost to follow up and 20 subjects did not undergo bleb assessments at 6 months.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Height</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.3" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.4" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.9" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.7" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascularity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.2" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.2" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medications</title>
        <description>Number of intraocular pressure lowering medications used by the patient at follow up visit.</description>
        <time_frame>6 months</time_frame>
        <population>In the injection group, 14 subjects were lost to follow up and 1 subject did not have medications documented at 6 months. In the sponge group, 10 subjects were lost to follow up and 2 subjects did not have medications documented at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Injection Group</title>
            <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Sponge Group</title>
            <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
          </group>
        </group_list>
        <measure>
          <title>Medications</title>
          <description>Number of intraocular pressure lowering medications used by the patient at follow up visit.</description>
          <population>In the injection group, 14 subjects were lost to follow up and 1 subject did not have medications documented at 6 months. In the sponge group, 10 subjects were lost to follow up and 2 subjects did not have medications documented at 6 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity</title>
        <description>Change in visual acuity from baseline</description>
        <time_frame>6 months</time_frame>
        <population>In the injection group, 14 subjects were lost to follow up at 6 months. In the sponge group, 10 subjects were lost to follow up at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Injection Group</title>
            <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Sponge Group</title>
            <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Change in visual acuity from baseline</description>
          <population>In the injection group, 14 subjects were lost to follow up at 6 months. In the sponge group, 10 subjects were lost to follow up at 6 months.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.03" lower_limit="-0.09" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Complications</title>
        <description>Number of eyes that experienced surgical complications following surgery</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injection Group</title>
            <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Sponge Group</title>
            <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Complications</title>
          <description>Number of eyes that experienced surgical complications following surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypotony Maculopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choroidal Effusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Additional Surgery</title>
        <description>Number of eyes requiring additional surgery from each group</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injection Group</title>
            <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Sponge Group</title>
            <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Additional Surgery</title>
          <description>Number of eyes requiring additional surgery from each group</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trab Revision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Xen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trabectome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CEIOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Interventions</title>
        <description>Mean number of postoperative interventions (needling, antifibrotic injections) performed in each group</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injection Group</title>
            <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Sponge Group</title>
            <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Interventions</title>
          <description>Mean number of postoperative interventions (needling, antifibrotic injections) performed in each group</description>
          <units>number of procedures</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5FU Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.2" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laser suture lysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.5" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Injection Group</title>
          <description>MMC delivered by preoperative subconjunctival injection
Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection</description>
        </group>
        <group group_id="E2">
          <title>Sponge Group</title>
          <description>MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Mitomycin-C sponge: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotony maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Choroidal effusions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jiun Do</name_or_title>
      <organization>UCSD Shiley Eye Institute</organization>
      <phone>8585346290</phone>
      <email>jiundo@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

